Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Merck Serono in-licenses Ono's S1P receptor agonist

Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528) granted Merck Serono exclusive rights outside of Japan, Korea

Read the full 153 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE